Company: DMAAR
Filing Date: 2025-01-22
Form Type: POS AM
Source: 0001213900-25-005176
Chunk: 110

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-22
Form: POS AM
Chunk 110
---
 influence over actions requiring a shareholder vote at least until the completion of our initial business combination. The non-managing sponsor investors have expressed an interest to purchase units in this offering, which, depending on how many units are purchased by the non-managing sponsor investors, could reduce the trading volume, volatility and liquidity for our shares, adversely affect the trading price of our shares and, further, may present a conflict of interest for such non-managing sponsor investors in determining whether a particular target business is an appropriate business with which to effectuate our initial business combination. The non -managingsponsor investors have expressed to us an interest in purchasing up to an aggregate of approximately $39.8million of the units in this offering at the offering price (assuming the exercise in full of the underwriters’ over -allotmentoption), or up to 19.9% of this offering. None of the non -managingsponsor investors has expressed to us an interest in purchasing more than 9.9% of the units to be sold in this offering, except one non -managingsponsor investor has expressed to us an interest in purchasing 19.9% of the units to be sold in this offering. Because these expressions of interest are not binding agreements or commitments to purchase, non -managingsponsor investors may determine to purchase fewer units in this offering, more units in this offering, or none at all. In addition, the underwriters have full discretion to allocate the units to investors and may determine to sell fewer units to the non -managingsponsor investors, or none at all, and the purchase of the non -managingsponsor membership interests is not contingent upon the participation in this offering or vice -versa. Depending on how many units are purchased by the non -managingsponsor investors, the post -offeringtrading volume, volatility and liquidity of our securities may be reduced relative to what they would have been had the units been more widely offered and sold to other public investors. We do not expect any purchase of units by the non -managingsponsor investors to negatively impact our ability to meet Nasdaq listing eligibility requirements as we expect to comply with all of the Nasdaq listing requirements prior to the effective date of the registration statement of which this prospectus forms a part. Although we have no knowledge of any affiliation or other agreement or arrangement, as to voting of our securities or otherwise, among the non -managingsponsor investors, if such investors all elect to purchase the full amount of